India Globalization Capital Inc is engaged in the development of cannabis-based combination therapies to treat Alzheimer's, pain, nausea, eating disorders, several endpoints of Parkinson's, and epilepsy in humans, dogs, and cats. The company has focused on four products that it is preparing for medical trials, Natrinol, Caesafin, Serosapse, and Hyalolex.